OABI
NASDAQ · Life Sciences Tools & Services
Omniab Inc
$3.96
+0.14 (+3.66%)
Financial Highlights (FY 2026)
Revenue
24.24M
Net Income
-84,113,205
Gross Margin
98.4%
Profit Margin
-347.0%
Rev Growth
-31.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.4% | 98.4% | 31.4% | 31.4% |
| Operating Margin | -369.5% | -332.5% | 6.8% | 7.4% |
| Profit Margin | -347.0% | -329.7% | 5.9% | 5.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.24M | 35.59M | 184.39M | 150.46M |
| Gross Profit | 23.85M | 35.01M | 57.85M | 47.20M |
| Operating Income | -89,568,104 | -118,354,564 | 12.45M | 11.10M |
| Net Income | -84,113,205 | -111,146,504 | 10.85M | 8.86M |
| Gross Margin | 98.4% | 98.4% | 31.4% | 31.4% |
| Operating Margin | -369.5% | -332.5% | 6.8% | 7.4% |
| Profit Margin | -347.0% | -329.7% | 5.9% | 5.9% |
| Rev Growth | -31.9% | -31.9% | +2.4% | +24.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 119.74M | 97.60M |
| Total Equity | — | — | 186.51M | 185.21M |
| D/E Ratio | — | — | 0.64 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -72,782,045 | -101,516,580 | 16.49M | 14.30M |
| Free Cash Flow | — | — | 4.93M | 6.48M |